Biomaterial Database

[Superficial lymph node metastasis from ovarian cancer--an analysis of 31 cases]. 1990

Y J Hou

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.

From March 1958 to June 1988, 53 cases of ovarian cancer with superficial lymph node metastasis (SLM) were treated in our hospital comprising 5.6% of patients with malignant ovarian tumors in the same period. Of 53 cases, 31 were proven by histopathology, and 27 had serous adenocarcinoma. Of these 31 cases, 15 with Stage IV lesion had SLM at time when first seen in the clinic and the others developed SLM during treatment or afterwards. The median survival was 34.7, 11.8 and 12.9 months in Grades I, II and III, respectively. Prognosis is related to pathological grade. The median survival was 36.5 months in 10/31 patients treated with surgery combined with chemotherapy and radiotherapy, 9.1 months in 6/31 treated with surgery plus chemotherapy, 22.4 months in 3/31 treated with radiotherapy only and 8.5 months in 6/31 treated with chemotherapy only. It is suggested that aggressive treatment can improve survival.

UI	MeSH Term	Description	Entries
D008207	Lymphatic Metastasis	Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.	Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010051	Ovarian Neoplasms	Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D003131	Combined Modality Therapy	The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.	Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003536	Cystadenocarcinoma	A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	Cystadenocarcinomas
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D015996	Survival Rate	The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.	Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival